HER2-Positive Metastatic Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

HER2-Positive Metastatic Breast Cancer Market Outlook

Thelansis’s “HER2-Positive Metastatic Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HER2-Positive Metastatic Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

HER2-Positive Metastatic Breast Cancer Overview

HER2-Positive Metastatic Breast Cancer is characterized by the overexpression and amplification of the human epidermal growth factor receptor 2 (HER2). It is a highly aggressive subtype with unfavorable survival prospects. Approximately 15% to 20% of breast cancers exhibit amplification of the HER2 gene, which is linked to an elevated risk of systemic metastasis and poor survival rates. Three primary indicators of HER2-positive breast cancer should promptly alert a physician: Nipple discharge, Sudden nipple inversion, and Changes in the texture of the breast skin. Currently, HER2 status can be determined through two tests on biopsy samples: immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Over the years since its approval, various HER2-targeted therapies have been developed, including Trastuzumab (Herceptin®), Pertuzumab (Perjeta®), Margetuximab (Margenza®), Lapatinib (Tykerb®), Neratinib (Nerlynx®), Tucatinib (Tukysa®), Ado-trastuzumab emtansine (T-DM1/Kadcyla®), and Trastuzumab deruxtecan (T-DXd/Enhertu®).

• Breast cancer is the most prevalent cancer among women in the United States. In 2023, it is estimated that 297,790 women and 2,800 men will receive a breast cancer diagnosis. Among these cases, HER2-positive breast cancer comprises about 20%. Additionally, HER2-low breast cancers, which exhibit low levels of HER2, represent an additional 55% of all breast cancer cases.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: